Technology

Biotectix is developing a new class of bioactive conductive polymer electrodes and coatings for electrodes that result in a fully integrated electrode-tissue interface. A number of benefits are driven by this platform technology without changing device size, shape, or implant procedure, including:

Improved Biocompatibility, Tissue Response

• Drug, biomolecule release
• Non-fouling surfaces
• Soft, compliant polymer coatings

Improved Electrical Performance

• Extended battery life
• High effective surface area
• Reduced electrode impedance (increase recording sensitivity)
• Enhanced charge transfer (higher current density, lower voltages)

These benefits will lead to reduced surgical complications, fewer hardware complications, and a reduced need for surgery to replace device batteries. Biotectix’s technology consists of three major elements that include an electrically conductive substrate, a biological component, and a conductive polymer.

The Biotectix technology platform addresses key shortcomings associated with traditional metallic biomedical device electrodes made of steel, platinum, iridium, or gold – which are hard and energy inefficient, exhibit limited biocompatibility, and can damage or cause serious inflammation and scarring of the local tissue. The traditional devices also have limited-MRI compatibility, and they often don’t function for as long or as well as intended, leading to more frequent battery replacement.

Biotectix’s technology platform has broad utility for many applications. The company’s novel materials and coatings can be used to improve pacemakers, cortical probes, cochlear implants, glucose sensors, and deep brain stimulators, among other implantable medical devices. Drug-eluting stents, prosthetic limb devices and intra-operative electrodes represent additional applications.